Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Ovarian Neoplasms × Etoposide × Clear all

Phase

Status

Sponsor Class

OTHER 18 NIH 3 NETWORK 3 INDUSTRY 3 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 3 Multiple Myeloma 2 Hematologic Neoplasms 2 Ovarian Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Gastro-enteropancreatic neuroendocrine tumor 1 Fallopian Tube Neoplasms 1

Interventions

apatinib 3 pembrolizumab 2 Poly(ADP-ribose) Polymerase Inhibitors 2 Hyperthermic Intraperitoneal Chemotherapy 2 Bevacizumab 2 taxane 1 olaparib 1 lenvatinib 1 fludarabine 1 cediranib 1 Whole Genome Sequencing 1 Valproic Acid 1 Tranexamic Acid 1 Tai Ji 1 Surgical Procedures, Operative 1 Sequence Analysis, RNA 1 Saline Solution 1 Radiation 1 Qigong 1 Propranolol 1 Positron Emission Tomography Computed Tomography 1 Population Groups 1 Platinum 1 Paclitaxel 1 Neoadjuvant Therapy 1 Interleukin-2 1 Hydralazine 1 Gene Expression 1 Etoposide 1 Etodolac 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01669226 2016-12-19

AICE

Shanghai Gynecologic Oncology Group

Phase 2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡